Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Isotechnika inc. (T.ISA)

No earlier versions found for this Subject.

Return to Isotechnika inc. (T.ISA)

isotechnika.com

Isotechnika is a life-sciences company headquartered in Edmonton, Alberta, Canada. The Company's lead drug is ISATX247; a novel drug platform designed to prevent organ rejection following transplantation as well as the treatment of autoimmune diseases. Isotechnika also globally markets and distributes its internally developed breath-test diagnostic product line. One of these products, the Helikit, is regarded as the gold standard for the diagnosis of ulcers. TEL: (780) 487 1600 Dr. Robert Foster, Chairman & CEO, FAX: (780) 484 4105 Isotechnika Inc. Email: rfoster@incentre.net TEL: (780) 487 1600 Dr. Randall Yatscoff, President & COO, FAX: (780) 484 4105 Isotechnika Inc. Email: yatscoffr@attcanada.net